Titre : Sites d'épissage d'ARN

Sites d'épissage d'ARN : Questions médicales fréquentes

Termes MeSH sélectionnés :

Drug Compounding
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Sites d'épissage d'ARN : Questions médicales les plus fréquentes", "headline": "Sites d'épissage d'ARN : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Sites d'épissage d'ARN : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-14", "dateModified": "2025-02-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Sites d'épissage d'ARN" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composants de gène", "url": "https://questionsmedicales.fr/mesh/D040461", "about": { "@type": "MedicalCondition", "name": "Composants de gène", "code": { "@type": "MedicalCode", "code": "D040461", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.340.024.340.137" } } }, "about": { "@type": "MedicalCondition", "name": "Sites d'épissage d'ARN", "alternateName": "RNA Splice Sites", "code": { "@type": "MedicalCode", "code": "D022821", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Přemysl Souček", "url": "https://questionsmedicales.fr/author/P%C5%99emysl%20Sou%C4%8Dek", "affiliation": { "@type": "Organization", "name": "Centre for Cardiovascular Surgery and Transplantation, 65691, Brno, Czech Republic. premysl.soucek@cktch.cz." } }, { "@type": "Person", "name": "Tomáš Freiberger", "url": "https://questionsmedicales.fr/author/Tom%C3%A1%C5%A1%20Freiberger", "affiliation": { "@type": "Organization", "name": "Centre for Cardiovascular Surgery and Transplantation, 65691, Brno, Czech Republic." } }, { "@type": "Person", "name": "Matthew R Gazzara", "url": "https://questionsmedicales.fr/author/Matthew%20R%20Gazzara", "affiliation": { "@type": "Organization", "name": "Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Phildelphia, United States." } }, { "@type": "Person", "name": "Yoseph Barash", "url": "https://questionsmedicales.fr/author/Yoseph%20Barash", "affiliation": { "@type": "Organization", "name": "Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Phildelphia, United States." } }, { "@type": "Person", "name": "Akihide Yoshimi", "url": "https://questionsmedicales.fr/author/Akihide%20Yoshimi", "affiliation": { "@type": "Organization", "name": "Division of Cancer RNA Research, National Cancer Center Research Institute." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Compounded medications for cardiovascular use in neonatology: an integrative review.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36102396", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/1984-0462/2023/41/2021167" } }, { "@type": "ScholarlyArticle", "name": "Impact of Apparatus and Adapter on In vitro Drug Release of Ophthalmic Semisolid Drug Products.", "datePublished": "2023-09-07", "url": "https://questionsmedicales.fr/article/37679656", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11095-023-03586-x" } }, { "@type": "ScholarlyArticle", "name": "Economic Considerations and Cost-Saving Strategies for Nonsterile Compounding Education.", "datePublished": "2023-07-16", "url": "https://questionsmedicales.fr/article/37454811", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajpe.2023.100571" } }, { "@type": "ScholarlyArticle", "name": "Advancing algorithmic drug product development: Recommendations for machine learning approaches in drug formulation.", "datePublished": "2023-08-09", "url": "https://questionsmedicales.fr/article/37562550", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejps.2023.106562" } }, { "@type": "ScholarlyArticle", "name": "Accelerated Predictive Stability Study of a Pediatric Drug Product for a Supplemental New Drug Application.", "datePublished": "2024-06-06", "url": "https://questionsmedicales.fr/article/38844721", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1208/s12249-024-02848-0" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Structures génétiques", "item": "https://questionsmedicales.fr/mesh/D040342" }, { "@type": "ListItem", "position": 4, "name": "Génome", "item": "https://questionsmedicales.fr/mesh/D016678" }, { "@type": "ListItem", "position": 5, "name": "Composants de génome", "item": "https://questionsmedicales.fr/mesh/D040481" }, { "@type": "ListItem", "position": 6, "name": "Gènes", "item": "https://questionsmedicales.fr/mesh/D005796" }, { "@type": "ListItem", "position": 7, "name": "Composants de gène", "item": "https://questionsmedicales.fr/mesh/D040461" }, { "@type": "ListItem", "position": 8, "name": "Sites d'épissage d'ARN", "item": "https://questionsmedicales.fr/mesh/D022821" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Sites d'épissage d'ARN - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Sites d'épissage d'ARN", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Sites d'épissage d'ARN", "description": "Comment identifier un site d'épissage ?\nQuels tests sont utilisés pour le diagnostic ?\nLes mutations affectent-elles le diagnostic ?\nQuels outils bioinformatiques sont utilisés ?\nComment les anomalies sont-elles détectées ?", "url": "https://questionsmedicales.fr/mesh/D022821?mesh_terms=Drug+Compounding&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Sites d'épissage d'ARN", "description": "Quels symptômes sont liés aux défauts d'épissage ?\nLes symptômes varient-ils selon les mutations ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes apparaissent-ils tôt ?\nComment les symptômes évoluent-ils ?", "url": "https://questionsmedicales.fr/mesh/D022821?mesh_terms=Drug+Compounding&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Sites d'épissage d'ARN", "description": "Peut-on prévenir les défauts d'épissage ?\nLe dépistage prénatal est-il utile ?\nQuels facteurs environnementaux influencent ?\nL'alimentation joue-t-elle un rôle ?\nLe suivi médical est-il important ?", "url": "https://questionsmedicales.fr/mesh/D022821?mesh_terms=Drug+Compounding&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Sites d'épissage d'ARN", "description": "Quels traitements existent pour les défauts d'épissage ?\nLa thérapie génique est-elle efficace ?\nY a-t-il des traitements symptomatiques ?\nLes traitements sont-ils personnalisés ?\nDes essais cliniques sont-ils disponibles ?", "url": "https://questionsmedicales.fr/mesh/D022821?mesh_terms=Drug+Compounding&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Sites d'épissage d'ARN", "description": "Quelles complications peuvent survenir ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des complications à long terme ?\nLes complications varient-elles selon les individus ?", "url": "https://questionsmedicales.fr/mesh/D022821?mesh_terms=Drug+Compounding&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Sites d'épissage d'ARN", "description": "Quels sont les facteurs de risque génétiques ?\nL'âge parental influence-t-il le risque ?\nLes infections pendant la grossesse sont-elles un risque ?\nL'exposition à des produits chimiques est-elle un facteur ?\nLe mode de vie influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D022821?mesh_terms=Drug+Compounding&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier un site d'épissage ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par analyse bioinformatique et séquençage de l'ARN." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'électrophorèse et le séquençage de l'ARN." } }, { "@type": "Question", "name": "Les mutations affectent-elles le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les mutations dans les sites d'épissage peuvent entraîner des erreurs de diagnostic." } }, { "@type": "Question", "name": "Quels outils bioinformatiques sont utilisés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des outils comme SpliceAI et MaxEntScan aident à prédire les sites d'épissage." } }, { "@type": "Question", "name": "Comment les anomalies sont-elles détectées ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les anomalies sont détectées par des analyses de l'ARN et des tests génétiques." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux défauts d'épissage ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des troubles neurologiques et des anomalies congénitales." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les mutations ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes dépendent du type de mutation et du gène affecté." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Surveillez les signes de fatigue, de douleur musculaire et de troubles cognitifs." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils tôt ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent apparaître dès la naissance, d'autres plus tard." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "L'évolution des symptômes peut être progressive ou soudaine, selon la condition." } }, { "@type": "Question", "name": "Peut-on prévenir les défauts d'épissage ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais le conseil génétique peut aider les familles à risque." } }, { "@type": "Question", "name": "Le dépistage prénatal est-il utile ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage prénatal peut identifier certains risques de défauts d'épissage." } }, { "@type": "Question", "name": "Quels facteurs environnementaux influencent ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'exposition à des toxines peuvent influencer les défauts d'épissage." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut réduire certains risques, mais ne prévient pas tous les défauts." } }, { "@type": "Question", "name": "Le suivi médical est-il important ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi médical régulier peut aider à détecter précocement des anomalies." } }, { "@type": "Question", "name": "Quels traitements existent pour les défauts d'épissage ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la thérapie génique et les médicaments ciblés." } }, { "@type": "Question", "name": "La thérapie génique est-elle efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être efficace pour corriger certains défauts d'épissage, mais pas tous." } }, { "@type": "Question", "name": "Y a-t-il des traitements symptomatiques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements symptomatiques peuvent aider à gérer les symptômes associés." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques." } }, { "@type": "Question", "name": "Des essais cliniques sont-ils disponibles ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des essais cliniques évaluent de nouvelles thérapies pour ces conditions." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles neurologiques et des maladies métaboliques." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent gravement affecter la qualité de vie, nécessitant un soutien continu." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent inclure des handicaps physiques ou mentaux." } }, { "@type": "Question", "name": "Les complications varient-elles selon les individus ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent varier considérablement d'un individu à l'autre." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque génétiques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de maladies génétiques augmentent le risque de défauts d'épissage." } }, { "@type": "Question", "name": "L'âge parental influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge avancé des parents peut augmenter le risque de mutations génétiques." } }, { "@type": "Question", "name": "Les infections pendant la grossesse sont-elles un risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections peuvent affecter le développement embryonnaire et augmenter les risques." } }, { "@type": "Question", "name": "L'exposition à des produits chimiques est-elle un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de défauts d'épissage." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire certains risques, mais ne les élimine pas complètement." } } ] } ] }

Sources (10000 au total)

Compounded medications for cardiovascular use in neonatology: an integrative review.

To analyze the profile of the compounded cardiovascular medicines prescribed in neonatology in Brazil.... An integrative bibliographic review was carried out, including studies published in the last 20 years. The used descriptors were: Intensive Care Neonatal, Off-Label Use, Pharmaceutical Preparations, i... The profile of routine prescrption in the neonatal unit was evaluated. The main cardiovascular medications prescribed as compounding formulation were: Spironolactone, Captopril, Furosemide, Hydrochlor... It was possible to analyze the profile of compounded cardiovascular medicines prescribed in neonatology in Brazil. The results showed the need for the development of medications suitable for the neona...

Impact of Apparatus and Adapter on In vitro Drug Release of Ophthalmic Semisolid Drug Products.

In vitro release testing (IVRT) is a widely used tool for evaluating the quality and performance of drug products. However, standardized sample adaptors or drug release apparatus setups for IVRT studi... Dexamethasone (DEX), a steroidal ingredient commonly used in ophthalmic drug products, was selected as a model drug. Ointments were prepared by mixing DEX in white petrolatum using a high shear mixer.... The sample adaptor setups had a minimal impact on cumulative drug release amount per area or release rate while USP IV apparatus with agitated flow enhanced drug release rates. The USP apparatus I wit... USP apparatuses and sample adaptors are critical considerations for IVRT. Two-sided semisolid adapter provides higher cumulative release, facilitating the discrimination between low drug content ophth...

Economic Considerations and Cost-Saving Strategies for Nonsterile Compounding Education.

To determine the economic considerations, including cost-saving strategies, associated with nonsterile compounding education for students in schools and colleges of pharmacy across the United States.... An electronic survey was sent to the American Association of Colleges of Pharmacy Pharmaceutics Section and Laboratory Instructor's Special Interest Group members. Quantitative and qualitative data we... Of 555 surveys sent, 46 were completed. Reported annual compounding budgets ranged from $3000 to $96,000. Reported annual equipment maintenance costs ranged from $400 to $18,000. Fifty percent of resp... Findings from this study may assist pharmacy administrators and course directors in evaluating the costs associated with nonsterile compounding education across the Academy and, more importantly, dete...

Magistral Compounding with 3D Printing: A Promising Way to Achieve Personalized Medicine.

Magistral compounding has always been an integral part of pharmacy practice. The increasing demand worldwide for personalized drug treatments might be accommodated by an increase in magistral compound... To investigate how 3D printing can be integrated into the existing compounding system by taking regulatory, economic, and profession-oriented aspects into account.... Semi-structured interviews were conducted with relevant Dutch stakeholders representing various health institutions, such as health ministries and boards, professional bodies, and different types of p... A total of 15 Dutch stakeholders were interviewed. It was found that the prevalence of compounding in community pharmacies in the Netherlands has decreased as a result of the practice shifting to spec... In the Netherlands, specialized compounding pharmacies have largely taken over compounding activities. 3D printing could be introduced within this system; however, challenges regarding how to regulate...